Lipid management in the prevention of stroke: A meta-analysis of fibrates for stroke prevention

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Zhou, Yu Hao ^a   Ye, Xiao Fei ^a   Yu, Fei Fei ^a   Zhang, Xiao ^a   Qin, Ying Yi ^a   Lu, Jian ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Fibrates; Meta analysis; Stroke

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; LIPID; PLACEBO; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; FOLLOW UP; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW;

DATABASES, FACTUAL; FEMALE; FIBRIC ACIDS; HUMANS; LIPID METABOLISM; MALE; STROKE;

EID: 84871717704     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-1     Document Type: Article

References (33)

1. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 1999, 30:2523-2528. 10.1161/01.STR.30.12.2523, 10582972.
2. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases, I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104:2746-2753. 10.1161/hc4601.099487, 11723030.
3. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997, 96:2137-2143. 10.1161/01.CIR.96.7.2137, 9337181.
4. Syvanne M, Nieminen MS, Frick MH, et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with Gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998, 98:1993-1999. 10.1161/01.CIR.98.19.1993, 9808595.
5. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009, 8:453-463. 10.1016/S1474-4422(09)70058-4, 19375663.
6. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506. 10.1161/01.CIR.82.2.495, 2372896.
7. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245. 10.1056/NEJM198711123172001, 3313041.
8. The BIP study group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) study. Circulation 2000, 102:21-27. The BIP study group.
9. Brunzell JD. Hypertriglyceridemia. N Engl J Med 2007, 357:1009-1017. 10.1056/NEJMcp070061, 17804845.
10. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418. 10.1056/NEJM199908053410604, 10438259.
11. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analysis: The PRISMA Statement. Plos Medicine 2009, 6.
12. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12. 10.1016/0197-2456(95)00134-4, 8721797.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
14. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005, 25:646-654. 10.1177/0272989X05282643, 16282215.
15. Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 2008, chap 9. Oxford, UK: The Cochrane Collaboration, Higgins J, Green S.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
17. Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral ascular disease. Atherosclerosis 1972, 15:177-183. 10.1016/0021-9150(72)90067-6, 4579955.
18. The Veterans Administration Cooperative Study Group The treatment of cerebrovascular disease with clofibrate. Final report of the veterans administration cooperative study of atherosclerosis, Neurology Section. Stroke 1973, 4:684-693. The Veterans Administration Cooperative Study Group.
19. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381. The Coronary Drug Project Research Group.
20. W.H.O Cooperative trial committee of principal investigators A co-operative trial in the primary prevention of ischemic heart disease using clofibrate, report from the committee of principal investigators. Br Heart J 1978, 40:1069-1118. 483536, 361054, W.H.O Cooperative trial committee of principal investigators.
21. Meade TW. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease. Curr Control Trials Cardiovasc Med 2001, 2:195-204. 10.1186/CVM-2-4-195, 57751, 11806795.
22. Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002, 325:1139. 10.1136/bmj.325.7373.1139, 133451, 12433762.
23. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005, 142:95-104.
24. The FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861. The FIELD study investigators.
25. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1563-1574. 2879499, 20228404, The ACCORD Study Group.
26. Duvall S, Tweedie R. A nonparametric " trim and fill" method for assessing publication bias in meta-analysis. J Am Stat Assoc 2000, 95:89-98.
27. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study Group.
28. LIPID Study Group Prevention of cardiovascular events and death with pravaststin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998, 339:1349-1357. LIPID Study Group.
29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996, 335:1001-1009. 10.1056/NEJM199610033351401, 8801446.
30. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. New Engl J Med 2000, 343:317-326. 10.1056/NEJM200008033430502, 10922421.
31. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischaemic stroke mortality. Stroke 1997, 28:83-87. 10.1161/01.STR.28.1.83, 8996494.
32. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study. Br Med J 1994, 309:11-15.
33. Prospective studies collaboration Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 45,0000 people in 45 prospective cohorts. Lancet 1995, 346:1647-1653. Prospective studies collaboration.